Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
BSX

Boston Scientific Corp

BSX

54.93USD-0.10 (-0.18%)Market Closed
Watchlist

Market Summary

USD54.93-0.10
Market Closed
-0.18%

BSX Alerts

  • 3 major insider sales recently.

BSX Stock Price

View Fullscreen

BSX RSI Chart

BSX Valuation

Market Cap

79.4B

Price/Earnings (Trailing)

87.11

Price/Sales (Trailing)

5.77

EV/EBITDA

26.13

Price/Free Cashflow

46.81

BSX Price/Sales (Trailing)

BSX Profitability

EBT Margin

11.28%

Return on Equity

5%

Return on Assets

2.71%

Free Cashflow Yield

2.14%

BSX Fundamentals

BSX Revenue

Revenue (TTM)

13.8B

Revenue Y/Y

11.26%

Revenue Q/Q

-2%

BSX Earnings

Earnings (TTM)

912.0M

Earnings Y/Y

3.85%

Earnings Q/Q

-14.01%

Price Action

Last 7 days

-1.5%

Last 30 days

5.5%

Last 90 days

2.2%

Trailing 12 Months

20.6%

How does BSX drawdown profile look like?

BSX Financial Health

Current Ratio

1.29

Debt/Equity

0.47

Debt/Cashflow

0.25

BSX Investor Care

Shares Dilution (1Y)

1.15%

Diluted EPS (TTM)

0.82

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202313.0B13.4B13.8B0
202212.2B12.3B12.6B12.7B
202110.1B11.2B11.5B11.9B
202010.8B10.2B10.1B9.9B
20199.9B10.1B10.4B10.7B
20189.3B9.5B9.7B9.8B
20178.6B8.7B8.8B9.0B
20167.7B8.0B8.2B8.4B
20157.4B7.3B7.4B7.5B
20147.2B7.2B7.3B7.4B
20137.1B7.1B7.1B7.1B
20127.6B7.4B7.3B7.2B
20117.8B7.8B7.8B7.6B
20108.1B8.0B7.9B7.8B
20098.0B8.1B8.1B8.2B
20088.3B8.2B8.1B8.1B
20070008.4B

Latest Insider Trading transactions for BSX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 03, 2023
mirviss jeffrey b.
acquired
-
-
649
evp&pres, periph intervent
Dec 03, 2023
mirviss jeffrey b.
sold (taxes)
-16,617
56.14
-296
evp&pres, periph intervent
Nov 20, 2023
butcher arthur c
sold
-447,509
54.06
-8,278
evp& grp pres, medsurg & apac
Nov 20, 2023
butcher arthur c
acquired
66,606
17.26
3,859
evp& grp pres, medsurg & apac
Nov 15, 2023
carruthers wendy
sold
-632,269
54.1744
-11,671
evp, human resources
Nov 15, 2023
carruthers wendy
acquired
94,953
14.818
6,408
evp, human resources
Nov 08, 2023
mirviss jeffrey b.
gifted
-
-
-4,000
evp&pres, periph intervent
Nov 06, 2023
mahoney michael f
sold
-5,951,980
52.507
-113,356
chairman, president & ceo
Nov 06, 2023
mahoney michael f
acquired
1,662,530
14.6664
113,356
chairman, president & ceo
Oct 16, 2023
carruthers wendy
sold
-581,063
49.7869
-11,671
evp, human resources

1–10 of 50

Which funds bought or sold BSX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Dec 06, 2023
Raleigh Capital Management Inc.
added
3.74
2,096
166,908
0.09%
Dec 06, 2023
CITIGROUP INC
added
2.5
70,409
122,224,000
0.09%
Dec 04, 2023
Phoenix Holdings Ltd.
added
85.77
6,402,050
14,188,700
0.13%
Dec 04, 2023
TUCKER ASSET MANAGEMENT LLC
added
53.12
856
2,587
-%
Dec 01, 2023
B. Riley Wealth Advisors, Inc.
reduced
-60.79
-1,385,300
859,056
0.02%
Nov 28, 2023
ASB Consultores, LLC
sold off
-100
-292,519
-
-%
Nov 28, 2023
IMA Wealth, Inc.
reduced
-1.59
-70,053
1,707,180
0.44%
Nov 27, 2023
OKABENA INVESTMENT SERVICES INC
sold off
-100
-16,822
-
-%
Nov 27, 2023
BANQUE PICTET & CIE SA
reduced
-12.27
-3,619,040
21,573,900
0.26%
Nov 27, 2023
TRUST CO OF VERMONT
added
43.51
69,172
241,719
0.02%

1–10 of 42

Latest Funds Activity

Are funds buying BSX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BSX
No. of Funds

Schedule 13G FIlings of Boston Scientific Corp

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
blackrock inc.
9.6%
137,802,646
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
8.29%
118,773,794
SC 13G/A
Feb 08, 2023
massachusetts financial services co /ma/
5.8%
82,467,469
SC 13G/A
Feb 06, 2023
wellington management group llp
4.03%
57,736,340
SC 13G/A
Jan 24, 2023
blackrock inc.
9.8%
140,116,265
SC 13G/A
Feb 09, 2022
vanguard group inc
7.83%
111,621,630
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G
Feb 08, 2022
blackrock inc.
9.0%
127,917,655
SC 13G/A
Feb 04, 2022
wellington management group llp
5.22%
74,421,509
SC 13G/A

Recent SEC filings of Boston Scientific Corp

View All Filings
Date Filed Form Type Document
Dec 07, 2023
4
Insider Trading
Dec 04, 2023
4
Insider Trading
Dec 04, 2023
4
Insider Trading
Nov 22, 2023
8-K
Current Report
Nov 21, 2023
4
Insider Trading
Nov 20, 2023
144
Notice of Insider Sale Intent
Nov 16, 2023
4
Insider Trading
Nov 15, 2023
144
Notice of Insider Sale Intent
Nov 09, 2023
4
Insider Trading
Nov 07, 2023
4
Insider Trading

BSX Fair Value

Loading...

Peers (Alternatives to Boston Scientific Corp)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
181.9B
40.0B
9.79% -0.70%
35.24
4.55
-11.26% -34.57%
71.3B
19.4B
-8.82% -4.53%
44.09
3.79
2.66% -16.58%
18.3B
15.0B
6.81% -29.70%
7.06
1.22
3.01% 209.09%
16.9B
3.8B
9.66% 15.63%
46.7
4.45
-1.48% -28.97%
MID-CAP
9.3B
12.7B
13.63% -12.11%
21
0.74
0.68% -30.25%
8.9B
2.7B
2.35% -23.26%
-55.55
3.25
-3.01% 97.36%
8.3B
3.4B
1.55% 18.98%
29.56
2.41
3.13% 18.17%
6.9B
3.9B
14.40% 9.17%
-31.57
1.75
-2.62% 73.28%
2.9B
342.6M
8.31% -12.22%
-244.83
8.56
42.19% 84.14%
2.5B
6.6B
-12.97% -7.64%
12.41
0.38
2.61% 0.62%
SMALL-CAP
1.1B
3.1B
3.77% -63.31%
-2.53
0.35
7.95% -550.16%
329.0M
163.3M
7.10% -27.48%
-13.39
2.01
7.14% -56.09%
282.7M
335.9M
6.52% -42.04%
43.86
0.84
4.71% 116.39%
72.1M
50.3M
-18.43% 13.66%
-4.75
1.43
3.23% 20.81%
5.2M
3.8M
8.25% -44.93%
-0.45
1.37
17.30% 10.67%

Boston Scientific Corp News

Latest updates
Clayton County Register08 Dec 202302:21 pm10 hours ago
Stockhouse Publishing05 Dec 202303:08 pm3 days ago
Mergers & Acquisitions04 Dec 202312:00 pm4 days ago
Fitch Ratings01 Dec 202303:54 pm7 days ago
Nasdaq30 Nov 202303:53 pm8 days ago
Nasdaq30 Nov 202312:00 am9 days ago
Morningstar21 Nov 202308:00 am17 days ago
Yahoo Finance17 Nov 202308:00 am21 days ago
Nasdaq17 Nov 202308:00 am21 days ago
Yahoo Finance14 Nov 202308:00 am24 days ago
GuruFocus.com14 Nov 202308:00 am24 days ago
GuruFocus.com13 Nov 202308:00 am25 days ago
Barron's13 Nov 202308:00 am25 days ago
MarketWatch10 Nov 202308:00 am28 days ago

Financials for Boston Scientific Corp

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue-2.0%3,5273,5993,3893,2423,1703,2443,0263,1272,9323,0772,7522,7092,6592,0032,5432,9042,7072,6312,4932,5612,393
Gross Profit-4.6%2,4262,5422,3492,2322,1912,2332,0712,1552,0322,1321,8581,7091,7901,2121,7372,0541,9301,8731,7631,8331,720
Operating Expenses-14.5%1,7332,0281,7971,8301,8331,8101,6051,9751,6451,8701,4881,6591,9951,2831,5911,8441,5471,4891,2221,5121,333
  S&GA Expenses-8.3%1,2421,3541,2151,1631,1321,1651,0601,1531,0661,1211,0191,0279847989781,0921,012968869953870
EBITDA Margin-100.0%-0.22*0.22*0.22*0.20*0.22*0.21*0.21*0.24*0.18*0.17*0.14*0.12*0.15*0.17*------
Interest Expenses-5.7%66.0070.0065.0064.0063.0064.0027987.0086.0086.0082.0096.0086.0091.0088.0018095.0089.0010965.0058.00
Income Taxes-32.7%10515613125657.0085.0045.0026.0064.00-37.00-16.0096.00-72.00-33.0012.00-4,002-35.00-9.0033.00-90.0024.00
Earnings Before Taxes43.2%610426444396245345156119483149325307-227-18122.00-6.0091.00145457296456
EBT Margin-100.0%-0.11*0.11*0.09*0.07*0.09*0.07*0.09*0.11*0.05*0.02*-0.01*-0.04*-0.01*0.02*------
Net Income-100.0%-27031414018826011095.00419186341210-155-14711.003,996126154424386432
Net Income Margin-100.0%-0.07*0.07*0.06*0.05*0.07*0.07*0.09*0.10*0.05*0.02*-0.01*0.37*0.39*0.40*------
Free Cashflow-100.0%-51579.00595320202-179212358537209514594201-177------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets1.3%34,04333,60132,89232,46931,94732,18932,33732,22931,87731,16830,90030,77730,84530,82330,11330,56526,75624,30923,80220,99920,379
  Current Assets10.5%6,5045,8865,7045,7605,1445,0835,0656,3176,2296,7586,1016,6946,1605,8034,8234,6994,8476,3346,2344,0033,971
    Cash Equivalents165.7%1,1324265709283382763252,1681,9472,6752,0161,7342,0221,724370607277123139829168
  Inventory6.8%2,4042,2502,0501,8671,7881,7521,7361,6101,6031,4301,4071,3511,4721,5161,6281,5791,5661,3001,2281,1661,134
  Net PPE4.0%2,6352,5342,4782,4462,2732,2462,2652,2522,1092,0822,0532,0842,0642,0792,0982,0791,9421,8201,7821,7821,730
  Goodwill-0.4%13,60813,65913,26912,92012,85212,88312,94911,98811,82010,87410,8689,95110,13710,10110,09810,17610,0158,4518,1797,9117,588
  Current Liabilities0.4%4,5794,5624,0833,8033,5493,8834,2754,2744,0224,0733,3933,6813,3023,1083,9764,8664,2544,8504,4795,2605,082
  Long Term Debt-1.3%8,3868,4948,4958,9158,5648,8029,0678,8048,8248,8479,0829,1309,3259,2789,3318,5929,5907,5917,5904,8034,806
Shareholder's Equity3.6%18,88618,22617,85017,57317,64017,25116,73516,62216,46215,94215,71915,32615,56415,61613,80413,8779,6999,4259,2338,7268,289
  Retained Earnings266.7%315-189-450-750-876-1,050-1,296-1,392-1,473-1,878-2,050-2,378-2,574-2,405-2,252-2,253-6,249-6,375-6,528-6,953-7,339
  Additional Paid-In Capital0.6%20,57320,44120,35620,28920,21920,10320,04319,98619,93019,81719,75019,73219,68719,59017,58917,56117,51017,42217,37417,34617,304
Shares Outstanding-100.0%-1,4461,436-1,4321,4301,428-1,4241,4211,419-1,4311,4111,3971,3951,3931,3911,3881,3851,383
Minority Interest-6.2%243259259------------------
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations6.1%698658190807470307-58.00478465643284673643269-77.0069250229235019.00501
  Share Based Compensation-1.7%59.0060.0055.0055.0058.0055.0052.0049.0051.0047.0047.0042.0040.0046.0042.0041.0042.0038.0036.0036.0036.00
Cashflow From Investing76.5%-197-840-484-183-225-29.00-1,574-461-1,207-71.00-147-129-59.00-76.00-49.00-3,962-620-410-595-662
Cashflow From Financing-62.8%16.0043.00-69.001.00-199-344-6.00-8.006.002.00-95.00-819-2491,105256-7241,3142562,127425151
  Dividend Payments-100.0%-14.0014.0013.0014.0014.0014.0013.0014.0014.0014.0014.0014.00--------

BSX Income Statement

2023-09-30
Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
Net sales$ 3,527$ 3,170$ 10,515$ 9,440
Cost of products sold1,1019793,1982,945
Gross profit2,4262,1917,3176,495
Operating expenses:    
Selling, general and administrative expenses1,2421,1323,8113,357
Research and development expenses3563391,051993
Royalty expense11113534
Amortization expense208202620604
Intangible asset impairment charges112558132
Contingent consideration net expense (benefit)12204368
Restructuring net charges (credits)1545118
Litigation-related net charges (credits)(111)0(111)42
Operating expenses1,7331,8335,5585,248
Operating income (loss)6933581,7591,247
Other income (expense):    
Interest expense(66)(63)(200)(406)
Other, net(18)(51)(78)(96)
Income (loss) before income taxes6102451,480745
Income tax expense (benefit)10557392188
Net income (loss)5041881,088558
Preferred stock dividends0(14)(23)(42)
Net income (loss) attributable to noncontrolling interests0000
Net income (loss) attributable to Boston Scientific common stockholders$ 505$ 174$ 1,065$ 516
Net income (loss) per common share — basic$ 0.34$ 0.12$ 0.74$ 0.36
Net income (loss) per common share — diluted$ 0.34$ 0.12$ 0.73$ 0.36
Weighted-average shares outstanding    
Basic1,464.51,431.61,448.81,429.7
Diluted1,475.01,440.01,459.11,438.7

BSX Balance Sheet

2023-09-30
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 952$ 928
Trade accounts receivable, net2,1011,970
Inventories2,4041,867
Prepaid income taxes307264
Other current assets741731
Total current assets6,5045,760
Property, plant and equipment, net2,6352,446
Goodwill13,60812,920
Other intangible assets, net5,8495,902
Deferred tax assets3,8403,942
Other long-term assets1,6051,500
TOTAL ASSETS34,04332,469
Current liabilities:  
Current debt obligations51320
Accounts payable929862
Accrued expenses2,2552,160
Other current liabilities882761
Total current liabilities4,5793,803
Long-term debt8,3868,915
Deferred income taxes91144
Other long-term liabilities1,8582,035
Commitments and contingencies
Stockholders’ equity  
Preferred stock, $0.01 par value - authorized 50,000,000 shares - 0 shares issued as of September 30, 2023 and 10,062,500 shares as of December 31, 202200
Common stock, $0.01 par value - authorized 2,000,000,000 shares - issued 1,728,158,524 shares as of September 30, 2023 and 1,696,633,993 shares as of December 31, 20221717
Treasury stock, at cost - 263,289,848 shares as of September 30, 2023 and December 31, 2022(2,251)(2,251)
Additional paid-in capital20,57320,289
Retained earnings/(Accumulated deficit)315(750)
Accumulated other comprehensive income (loss), net of tax231269
Total stockholders’ equity18,88617,573
Noncontrolling interests2430
Total equity19,12917,573
TOTAL LIABILITIES AND EQUITY$ 34,043$ 32,469
BSX
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, that uses in the treatment of coronary artery disease and aortic valve conditions. Further, it provides stents, balloon catheters, guidewires, atherectomy, and thrombectomy systems to treat arterial and venous diseases; and peripheral embolization devices, radioactive microspheres, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
 CEO
 WEBSITEwww.bostonscientific.com
 EMPLOYEES45000

Boston Scientific Corp Frequently Asked Questions


What is the ticker symbol for Boston Scientific Corp? What does BSX stand for in stocks?

BSX is the stock ticker symbol of Boston Scientific Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Boston Scientific Corp (BSX)?

As of Thu Dec 07 2023, market cap of Boston Scientific Corp is 79.6 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BSX stock?

You can check BSX's fair value in chart. The fair value of Boston Scientific Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Boston Scientific Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BSX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Boston Scientific Corp a good stock to buy?

The fair value guage provides a quick view whether BSX is over valued or under valued. Whether Boston Scientific Corp is cheap or expensive depends on the assumptions which impact Boston Scientific Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BSX.

What is Boston Scientific Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Dec 07 2023, BSX's PE ratio (Price to Earnings) is 87.28 and Price to Sales (PS) ratio is 5.79. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BSX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Boston Scientific Corp's stock?

In the past 10 years, Boston Scientific Corp has provided 0.167 (multiply by 100 for percentage) rate of return.